Trials / Completed
CompletedNCT01475695
GSK2251052 Mass Balance in Healthy Adult Subjects
An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2251052 Administered as a Single Intravenous Dose to Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 30 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Approximately 6 healthy male subjects will be administered a single 1500 mg intravenous dose of 14C-GSK2251052 under fasted conditions. Blood, urine and fecal samples will be collected for a minimum of 14 days following study drug administration. Safety and tolerability will be monitored throughout the study. A follow-up visit will occur 7-14 days after study drug administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 14C GSK2251052 | 1500 mg iv dose GSK2251052 |
Timeline
- Start date
- 2011-04-21
- Primary completion
- 2011-05-19
- Completion
- 2011-05-19
- First posted
- 2011-11-21
- Last updated
- 2017-06-28
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01475695. Inclusion in this directory is not an endorsement.